ArticleNature communications2023
Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 64 citations in OpenAlex.
- DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8Oncoimmunology · 2026Article
- Entering the Age of Specificity in T Cell Immunity.Immunological reviews · 2026Review
- Colorectal cancer and tumor vaccines (Review).Oncology letters · 2026Review
- HLA-II Expression Marks Activated and Clonally Expanded CD8International journal of molecular sciences · 2026Article
- Renaissance of antiviral CD8Nature reviews. Immunology · 2026Review
- SBRT embedded in low-dose RT plus αPD-1 (immuno-EclipseRT, iERT) elicits CD8Nature communications · 2026Article
- Hallmarks and correlates of effective adoptive cell immunotherapy for cancer.Nature reviews. Immunology · 2026Review
- Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next-Generation Approaches.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- PRECISE-seq reveals disease-relevant TCR repertoires with phenotypic plasticity.The Journal of experimental medicine · 2026Article
- T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy.Cancer immunology research · 2026Article
- TIGIT disruption rescues the antitumor activity of low avidity TCR-engineered T cells by increasing TCR signal strength.Nature communications · 2026Article
- Article
- Immuno-oncological Challenges and Chemoresistance in Veterinary Medicine: Probiotics as a New Strategic Tool.Probiotics and antimicrobial proteins · 2026Review
- Tumor-infiltrating lymphocyte expansion protocols for adoptive cell therapy in cancer.Cellular oncology (Dordrecht, Netherlands) · 2025Review
- Preclinical ex vivo and in vivo models to study immunotherapy agents and their combinations as predictive tools toward the clinic.Journal for immunotherapy of cancer · 2025Review
- Pathomic immune biomarkers define recurrence risk in early-stage melanoma.The oncologist · 2025Article
- Review
- Neoantigen-Driven Immunotherapy in Triple-Negative Breast Cancer: Emerging Strategies and Clinical Potential.Biomedicines · 2025Review
- Tumor antigens preferentially derive from unmutated genomic sequences in melanoma and non-small cell lung cancer.Nature cancer · 2025Article
- TRAIT: A Comprehensive Database for T-cell Receptor-antigen Interactions.Genomics, proteomics & bioinformatics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The success of cancer immunotherapy depends in part on the strength of antigen recognition by T cells. Here, we characterize the T cell receptor (TCR) functional (antigen sensitivity) and structural (monomeric pMHC-TCR off-rates) avidities of 371 CD8 T cell clones specific for neoantigens, tumor-associated antigens (TAAs) or viral antigens isolated from tumors or blood of patients and healthy donors. T cells from tumors exhibit stronger functional and structural avidity than their blood counterparts. Relative to TAA, neoantigen-specific T cells are of higher structural avidity and, consistently, are preferentially detected in tumors. Effective tumor infiltration in mice models is associated with high structural avidity and CXCR3 expression. Based on TCR biophysicochemical properties, we derive and apply an in silico model predicting TCR structural avidity and validate the enrichment in high avidity T cells in patients' tumors. These observations indicate a direct relationship between neoantigen recognition, T cell functionality and tumor infiltration. These results delineate a rational approach to identify potent T cells for personalized cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.